Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Goodwill & Intangibles Intangibles Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Short term Debt (2016 - 2025)

Arrowhead Pharmaceuticals' Short term Debt history spans 10 years, with the latest figure at $40.0 million for Q4 2025.

For Q4 2025, Short term Debt rose 2361.54% year-over-year to $40.0 million; the TTM value through Dec 2025 reached $40.0 million, up 2361.54%, while the annual FY2025 figure was $40.0 million, N/A changed from the prior year.
Short term Debt reached $40.0 million in Q4 2025 per ARWR's latest filing, roughly flat from $40.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $65.0 million in Q1 2025 to a low of $1.6 million in Q4 2024.